Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.

Expert review of gastroenterology & hepatology

Volumn 1, Issue 1, 2007, Pages 29-39

  Ko, Hin Hin ^a   Bressler, Brian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; MONOCLONAL ANTIBODY; NATALIZUMAB;

CLINICAL TRIAL; CROHN DISEASE; HUMAN; IMMUNOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; HUMANS; INTEGRIN ALPHA4;

EID: 61549125105     PISSN: None     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.1.1.29     Document Type: Review

References (30)